Article Details

FDA ODAC Committee Votes in Favor of Benefit-Risk Profile of Ide-Cel in Early R/R Myeloma

Retrieved on: 2024-03-15 21:27:46

Tags for this article:

Click the tags to see associated articles and topics

FDA ODAC Committee Votes in Favor of Benefit-Risk Profile of Ide-Cel in Early R/R Myeloma. View article details on hiswai:

Excerpt

... monoclonal antibody. 1. The committee discussed data from the phase 3 KarMMA-3 trial (NCT03651128), which showed that at a median follow-up of 18.6 ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo